ImmunityBio Inc. (NASDAQ:IBRX) presented two indirect treatment comparison analyses, highlighting efficacy and safety outcomes for ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary disease.
ImmunityBio Presents Comparative ANKTIVA Data
Something went wrong.
The presentations compared ANKTIVA (nogapendekin alfa inbakicept-pmln) combined with BCG against two FDA-approved therapies — Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg) and Johnson & Johnson’s (NYSE:JNJ) INLEXZO (TAR-200).
ANKTIVA Combo Showed Higher Response Rates Against Nadofaragene
